Join us and participate in the new developments in medicine
General Eligibility
Clinical Trials
Filter by enrollment status to find studies that may be right for you. We value your participation in advancing bladder cancer care.
Status: Active and Enrolling
The rBCG study is investigating recombinant Bacillus Calmette-Guérin (rBCG) as a treatment option for patients with non-muscle invasive bladder cancer. Researchers aim to evaluate whether this next-generation therapy can provide effective disease control while maintaining a favorable safety profile.
Status: Active and Enrolling
The AURA study is evaluating innovative therapies for bladder cancer and aims to improve treatment outcomes through advanced approaches to disease management. Researchers are studying the safety and effectiveness of these therapies in eligible patients.
Status: Active and Enrolling
The Cxbladder microDRIVE study is evaluating a noninvasive urine-based biomarker test designed to improve the detection and evaluation of bladder cancer. Researchers hope this technology will help reduce unnecessary procedures while supporting earlier diagnosis and more personalized care.
Eligibility criteria vary depending on the study. Patients may qualify for one or more clinical trials if they meet certain study-specific requirements. For additional study requirements and eligibility information, please contact our Research Department by emailing research@theupi.com or calling 210-617-3670 and selecting the Research option. A member of our team will be happy to answer your questions and discuss available study opportunities.
